These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 27737744)

  • 21. Residual inflammatory risk associated with interleukin-18 and interleukin-6 after successful interleukin-1β inhibition with canakinumab: further rationale for the development of targeted anti-cytokine therapies for the treatment of atherothrombosis.
    Ridker PM; MacFadyen JG; Thuren T; Libby P
    Eur Heart J; 2020 Jun; 41(23):2153-2163. PubMed ID: 31504417
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of Canakinumab vs Placebo on Survival Without Invasive Mechanical Ventilation in Patients Hospitalized With Severe COVID-19: A Randomized Clinical Trial.
    Caricchio R; Abbate A; Gordeev I; Meng J; Hsue PY; Neogi T; Arduino R; Fomina D; Bogdanov R; Stepanenko T; Ruiz-Seco P; Gónzalez-García A; Chen Y; Li Y; Whelan S; Noviello S;
    JAMA; 2021 Jul; 326(3):230-239. PubMed ID: 34283183
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sustained remission of symptoms and improved health-related quality of life in patients with cryopyrin-associated periodic syndrome treated with canakinumab: results of a double-blind placebo-controlled randomized withdrawal study.
    Koné-Paut I; Lachmann HJ; Kuemmerle-Deschner JB; Hachulla E; Leslie KS; Mouy R; Ferreira A; Lheritier K; Patel N; Preiss R; Hawkins PN;
    Arthritis Res Ther; 2011; 13(6):R202. PubMed ID: 22152723
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anticytokine Agents: Targeting Interleukin Signaling Pathways for the Treatment of Atherothrombosis.
    Ridker PM
    Circ Res; 2019 Feb; 124(3):437-450. PubMed ID: 30702995
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Interleukin-1β suppression dampens inflammatory leucocyte production and uptake in atherosclerosis.
    Hettwer J; Hinterdobler J; Miritsch B; Deutsch MA; Li X; Mauersberger C; Moggio A; Braster Q; Gram H; Robertson AAB; Cooper MA; Groß O; Krane M; Weber C; Koenig W; Soehnlein O; Adamstein NH; Ridker P; Schunkert H; Libby P; Kessler T; Sager HB
    Cardiovasc Res; 2022 Oct; 118(13):2778-2791. PubMed ID: 34718444
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sustained efficacy of the monoclonal anti-interleukin-1 beta antibody canakinumab in a 9-month trial in Schnitzler's syndrome.
    de Koning HD; Schalkwijk J; van der Ven-Jongekrijg J; Stoffels M; van der Meer JW; Simon A
    Ann Rheum Dis; 2013 Oct; 72(10):1634-8. PubMed ID: 23087179
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: results of a double-blind, randomised study.
    Schlesinger N; Mysler E; Lin HY; De Meulemeester M; Rovensky J; Arulmani U; Balfour A; Krammer G; Sallstig P; So A
    Ann Rheum Dis; 2011 Jul; 70(7):1264-71. PubMed ID: 21540198
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetic and pharmacodynamic properties of canakinumab, a human anti-interleukin-1β monoclonal antibody.
    Chakraborty A; Tannenbaum S; Rordorf C; Lowe PJ; Floch D; Gram H; Roy S
    Clin Pharmacokinet; 2012 Jun; 51(6):e1-18. PubMed ID: 22550964
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dry Eye Signs and Symptoms Persist During Systemic Neutralization of IL-1β by Canakinumab or IL-17A by Secukinumab.
    Grosskreutz CL; Hockey HU; Serra D; Dryja TP
    Cornea; 2015 Dec; 34(12):1551-6. PubMed ID: 26418434
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anti-Inflammatory Therapy With Canakinumab for the Prevention of Hospitalization for Heart Failure.
    Everett BM; Cornel JH; Lainscak M; Anker SD; Abbate A; Thuren T; Libby P; Glynn RJ; Ridker PM
    Circulation; 2019 Mar; 139(10):1289-1299. PubMed ID: 30586730
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Canakinumab: Promises and Future in Cardiometabolic Diseases and Malignancy.
    Dhorepatil A; Ball S; Ghosh RK; Kondapaneni M; Lavie CJ
    Am J Med; 2019 Mar; 132(3):312-324. PubMed ID: 30832770
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Relationship of Interleukin-1β Blockade With Incident Gout and Serum Uric Acid Levels: Exploratory Analysis of a Randomized Controlled Trial.
    Solomon DH; Glynn RJ; MacFadyen JG; Libby P; Thuren T; Everett BM; Ridker PM
    Ann Intern Med; 2018 Oct; 169(8):535-542. PubMed ID: 30242335
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Low-Dose Methotrexate for the Prevention of Atherosclerotic Events.
    Ridker PM; Everett BM; Pradhan A; MacFadyen JG; Solomon DH; Zaharris E; Mam V; Hasan A; Rosenberg Y; Iturriaga E; Gupta M; Tsigoulis M; Verma S; Clearfield M; Libby P; Goldhaber SZ; Seagle R; Ofori C; Saklayen M; Butman S; Singh N; Le May M; Bertrand O; Johnston J; Paynter NP; Glynn RJ;
    N Engl J Med; 2019 Feb; 380(8):752-762. PubMed ID: 30415610
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety of canakinumab in Schnitzler syndrome: A multicenter randomized placebo-controlled study.
    Krause K; Tsianakas A; Wagner N; Fischer J; Weller K; Metz M; Church MK; Maurer M
    J Allergy Clin Immunol; 2017 Apr; 139(4):1311-1320. PubMed ID: 27658762
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of acarbose on carotid intima-media thickness in patients with newly diagnosed impaired glucose tolerance or mild type 2 diabetes mellitus: A one-year, prospective, randomized, open-label, parallel-group study in Japanese adults with established coronary artery disease.
    Koyasu M; Ishii H; Watarai M; Takemoto K; Inden Y; Takeshita K; Amano T; Yoshikawa D; Matsubara T; Murohara T
    Clin Ther; 2010 Aug; 32(9):1610-7. PubMed ID: 20974318
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Early-stage atherosclerosis in newly diagnosed, untreated type 2 diabetes mellitus and impaired glucose tolerance.
    Gong W; Lu B; Yang Z; Ye W; Du Y; Wang M; Li Q; Zhang W; Pan Y; Feng X; Zhou W; Zhang Y; Yang Z; Yang Y; Zhu X; Hu R
    Diabetes Metab; 2009 Dec; 35(6):458-62. PubMed ID: 19879790
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Interventions for reducing inflammation in familial Mediterranean fever.
    Yin X; Tian F; Wu B; Xu T
    Cochrane Database Syst Rev; 2022 Mar; 3(3):CD010893. PubMed ID: 35349164
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of canakinumab on frailty: A post hoc analysis of the CANTOS trial.
    Orkaby AR; Thomson A; MacFadyen J; Besdine R; Forman DE; Travison TG; Ridker PM
    Aging Cell; 2024 Jan; 23(1):e14029. PubMed ID: 37927208
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of high-dose modified-release nicotinic acid on atherosclerosis and vascular function: a randomized, placebo-controlled, magnetic resonance imaging study.
    Lee JM; Robson MD; Yu LM; Shirodaria CC; Cunnington C; Kylintireas I; Digby JE; Bannister T; Handa A; Wiesmann F; Durrington PN; Channon KM; Neubauer S; Choudhury RP
    J Am Coll Cardiol; 2009 Nov; 54(19):1787-94. PubMed ID: 19874992
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial.
    Ridker PM; MacFadyen JG; Everett BM; Libby P; Thuren T; Glynn RJ;
    Lancet; 2018 Jan; 391(10118):319-328. PubMed ID: 29146124
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.